ArticleFuture virology2023

Oral bemnifosbuvir (AT-527) vs placebo in patients with mild-to-moderate COVID-19 in an outpatient setting (MORNINGSKY).

Arantxa Horga et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.